Answers are grounded in this paper and cite their sources.
Clinical evidence is an important consideration in drug reimbursement decisions, yet its role in the reimbursement of Chinese patent medicines (CPMs) remains poorly understood. This study examined the association between clinical trial evidence and reimbursement inclusion for CPMs. We identified 187 CPMs approved between January 2010 and June 2024, of which 125 met the eligibility criteria. Clinical trial evidence was characterized using an eight-domain evidence score and comparative clinical benefit. Associations with China’s National Reimbursement Drug List (NRDL) inclusion were estimated using Firth penalized logistic regression with adjustment for drug-level characteristics. Among 125 CPMs, 43 (34.40%) were included in the NRDL. In the fully adjusted model, each 1-point increase in the clinical trial evidence score was associated with greater odds of NRDL inclusion (OR, 2.19; 95% CI, 1.31–3.69; p = 0.003). Compared with CPMs for which clinical benefit was not reported, higher odds of inclusion were observed for those with a clinical benefit rate < 50% (OR, 13.51; 95% CI, 1.86–97.98; p = 0.010) and ≥ 50% (OR, 19.45; 95% CI, 1.79–211.07; p = 0.015). A higher clinical trial evidence score and the availability of estimable comparative clinical benefit were associated with greater odds of NRDL inclusion. Strengthening the design, conduct, and reporting of CPM clinical trials may support more evidence-informed reimbursement decisions and the continued standardization of CPM clinical research.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: